# Seed 2.1 Turbo — deep_reasoning/ethical_dilemma_structured

- model_id: `bytedance-seed/seed-2-1-turbo`
- success: True  | final: 6.8 | quality: 7.5
- latency_total: 36.467s | tokens_per_second: 56.2
- input_tokens: 240 | output_tokens: 2048

## Entrada exacta (lo que recibió el modelo)

**user:**

Una startup de IA tiene un modelo que puede detectar cancer con 95% de precision.
Sin embargo:
- El 5% de falsos positivos causa ansiedad severa y procedimientos innecesarios
- El modelo funciona peor en personas de piel oscura (90% precision vs 97% en piel clara)
- Lanzar ahora salvaria vidas pero con sesgo conocido
- Esperar 6 meses para corregir el sesgo significa que gente morira mientras tanto

El board te pide una recomendacion. Estructura tu analisis:
1. Identifica a todos los stakeholders afectados
2. Analiza los trade-offs cuantitativamente
3. Proporciona 3 opciones con pros/contras de cada una
4. Da tu recomendacion final con justificacion

No busques la respuesta "correcta" - busca la mejor argumentada.


## Respuesta completa


El usuario pide un análisis para una startup de IA con un modelo de detección de cáncer, whose core issues include 95% overall accuracy, harmful false positives, skin tone bias (90% detection rate for dark skin vs 97% for light skin), and the dilemma of launching now or waiting 6 months. I’ve confirmed the final output needs 4 sections: stakeholders, quantitative trade-offs, 3 options with pros and cons, and final recommendation. I’ve clarified the model is likely skin cancer detection from images, and sorted out relevant patient groups. I will clearly state all assumptions made during the analysis to avoid ambiguity, and have sorted out 5 additional core stakeholder groups covering clinical teams, the startup itself, healthcare systems, patient rights advocacy groups, and regulators.

I will categorize stakeholders by impact level for clearer structured analysis. I’ve set clear analysis assumptions: the model is a skin cancer detection tool used as a triage aid in primary care settings, and I will explicitly state all adopted assumptions to ensure transparency. I’ve set key analysis parameters: the prevalence of skin cancer among test users is 5%, the test population will be 100,000 people in 6 months, with 30% dark skin and 70% light skin, which fits demographics of regions like Latin America and the US.

I’ve clarified the damage assessment metrics: 5-year survival rate is 99% for early-detected melanoma and 27% for late-stage cases, with 10% of undetected melanomas progressing to life-threatening stages within 6 months.

I’ve decided to use lives saved, health adverse events and QALY as the core damage assessment metrics, with specific assumptions noted for adjustability. I will first list all assumptions then conduct quantitative trade-off calculations for the two launch scenarios. I have finalized the first three explicit core analysis assumptions, covering the model's application scenario, target population demographics and skin cancer prevalence in the target group.

I’ve adjusted the skin cancer prevalence parameters to align with real-world data: 6% for light skin groups and 2.67% for dark skin groups, keeping the overall total at 5%. I’ve also set the 6-month undetected mortality rate at 15% for dark skin patients and 8% for light skin patients.

I’ve confirmed that real-world data shows melanoma mortality is twice as high in Black patients as in white patients, primarily due to late detection. I’m now clarifying the definition of the model’s stated 95% overall accuracy, which is likely overall accuracy (accuracy = (true positives + true negatives)/total), with 5% false positives corresponding to 1 - specificity.
